Compare · LUCD vs RMD
LUCD vs RMD
Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCD and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.14B, about 436.9x LUCD ($75.9M).
- RMD has been more active in the news (22 items in the past 4 weeks vs 7 for LUCD).
- RMD has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- Lucid Diagnostics Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $75.9M
- $33.14B
- 1M return
- -
- -6.86%
- 1Y return
- -
- -5.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 22
- Recent ratings
- 6
- 25
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest LUCD
- PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
- Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- Oil Above $100 Puts Penny Stocks in Focus
Latest RMD
- Chairman and CEO Michael J. Farrell was granted 48,136 units of ResMed Common Stock and covered exercise/tax liability with 28,180 units of ResMed Common Stock, increasing direct ownership by 4% to 491,729 units (SEC Form 4) to satisfy withholding obligation
- Director Christopher Delorefice was granted 554 units of ResMed Common Stock, increasing direct ownership by 23% to 2,977 units (SEC Form 4)
- Global General Counsel Michael J Rider was granted 5,587 units of ResMed Common Stock and covered exercise/tax liability with 3,084 units of ResMed Common Stock, increasing direct ownership by 24% to 12,919 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Ronald R Taylor
- Director Harjit Gill was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 12,013 units (SEC Form 4)
- Director Desney Tan was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 18% to 7,111 units (SEC Form 4)
- Director John Hernandez was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 22% to 6,227 units (SEC Form 4)
- Director Karen Drexler was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 11,711 units (SEC Form 4)
- Chief Product Officer Justin Leong was granted 10,314 units of ResMed Common Stock (SEC Form 4)
- Director Carol Burt was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 51% to 3,265 units (SEC Form 4)